Rafferty Asset Management LLC Sells 80,319 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rafferty Asset Management LLC decreased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 595,472 shares of the company's stock after selling 80,319 shares during the period. Rafferty Asset Management LLC owned approximately 0.15% of Recursion Pharmaceuticals worth $4,025,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth $27,000. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares in the last quarter. NewEdge Advisors LLC grew its position in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the period. PNC Financial Services Group Inc. grew its position in Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after buying an additional 6,758 shares during the period. Finally, Colonial River Investments LLC bought a new position in Recursion Pharmaceuticals during the fourth quarter valued at about $68,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX traded down $0.06 on Friday, reaching $4.08. 16,650,890 shares of the company's stock were exchanged, compared to its average volume of 13,434,645. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -2.67 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The stock has a fifty day simple moving average of $5.14 and a 200-day simple moving average of $6.51.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.39) EPS. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.